A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.

• Status: Completed
• Trial end date: 2000-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the safety and tolerability of ZDV when given to premature infants born to HIV-positive women to prevent HIV infection.

ZDV has been used successfully to prevent the transmission of HIV from mother to child during pregnancy and birth. However, ZDV has been given to very few premature babies, and the best dose to use has not yet been determined.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Zidovudine

Criteria

Inclusion Criteria

Your baby may be eligible for this study if he/she:

• Requires ZDV (as decided by your doctor) because you are HIV-positive.

• Is 1-5 days old and was born prematurely.

Exclusion Criteria

Your baby will not be eligible for this study if he/she:

• Is not expected to live 6 weeks because of severe illness.

• Is having problems with blood pressure or is not urinating enough.